UroGen Pharma receives new U.S. patent allowance for RTGel technology

UroGen Pharma announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for patent application no. 18/535,108 entitled “Material and Method for Treating Cancer.” The allowed claims relate to the combination of UroGen’s RTGel technology with medac’s licensed proprietary lyophilized mitomycin formulation and cover the use of UroGen’s UGN-103 and UGN-104 development programs in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer and low-grade upper tract urothelial cancer, respectively. The U.S. patent, once issued, will have an expiration date in December 2041. In January, UroGen entered into a licensing and supply agreement with medac to develop UGN-103 for LG-IR-NMIBC and UGN-104 for LG-UTUC. In April, the FDA accepted UroGen’s IND application for UGN-103 and the company is currently onboarding clinical sites for the study. The company anticipates commencing a similar study for UGN-104, which is expected in early 2025.